Spontaneous Autoimmunity in the Absence of IL-2 Is Driven by Uncontrolled Dendritic Cells

Sara H. Isakson, Shoshana D. Katzman and Katrina K. Hoyer

J Immunol 2012; 189:1585-1593; Prepublished online 9 July 2012;
doi: 10.4049/jimmunol.1200342
http://www.jimmunol.org/content/189/4/1585

Supplementary Material
http://www.jimmunol.org/content/suppl/2012/07/09/jimmunol.1200342.DC1

References
This article cites 33 articles, 22 of which you can access for free at:
http://www.jimmunol.org/content/189/4/1585.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Spontaneous Autoimmunity in the Absence of IL-2 Is Driven by Uncontrolled Dendritic Cells

Sara H. Isakson, Shoshana D. Katzman, and Katrina K. Hoyer

BALB/c IL-2-deficient (IL-2–KO) mice develop systemic autoimmunity, dying within 3 to 5 wk from complications of autoimmune hemolytic anemia. Disease in these mice is Th1 mediated, and IFN-γ production is required for early autoimmunity. In this study, we show that dendritic cells (DCs) are required for optimal IFN-γ production by T cells in the IL-2–KO mouse. Disease is marked by DC accumulation, activation, and elevated production of Th1-inducing cytokines. IL-2–KO DCs induce heightened proliferation and cytokine production by naïve T cells compared with wild-type DCs. The depletion of either conventional or plasmacytoid DCs significantly prolongs the survival of IL-2–KO mice, demonstrating that DCs contribute to the progression of autoimmunity. Elimination of Th1-inducing cytokine signals (type 1 IFN and IL-12) reduces RBC-specific Ab production and augments survival, indicating that cytokines derived from both plasmacytoid DCs and conventional DCs contribute to disease severity. DC activation likely precedes T cell activation because DCs are functionally activated even in an environment lacking overt T cell activation. These data indicate that both conventional and plasmacytoid DCs are critical regulators in the development of this systemic Ab-mediated autoimmune disease, in large part through the production of IL-12 and type 1 IFNs. The Journal of Immunology, 2012, 189: 1585–1593.

A
utoimmune hemolytic anemia (AIHA) is an autoimmune disease caused by the production of Abs to RBCs. IL-2–deficient (IL-2–KO) mice on the BALB/C background develop systemic autoimmune disease, dying between 3 and 5 wk from complications of AIHA (1). IL-2 was traditionally thought to be a lymphocyte-activating and immune-stimulatory factor; however, it is now known that IL-2 is also required for the survival and function of regulatory T cells (Tregs) (2–4). The major known defect in IL-2–KO mice is a reduction in the percentage and functionality of peripheral Tregs that require IL-2 for their survival and optimal suppressive abilities.

Activation of helper CD4+ T cells is critical to autoimmune pathology in IL-2–KO mice (1, 5). We demonstrated previously that IFN-γ is required for production of the autoantibodies, with IL-2 × IFN-γ knockout (KO) mice surviving significantly longer than their IL-2–KO counterparts (6). IFN-γ-producing Th1 cells play a pathogenic role in many autoimmune diseases. In addition to stimulating class switching to IgG isotypes (7), IFN-γ stimulates the phagocytic function of macrophages and increases macrophage and dendritic cell (DC) responsiveness to other inflammatory signals, such as enhanced type 1 IFN (T1 IFN) responses (8). IFN-γ can also autoamplify the Th1 response.

Interactions between APCs and T cells are critical to the initiation of an immune response and differentiation of effector T cells. DCs as professional APCs are essential for initiating T-dependent immune responses and are pivotal to the determination of tolerance versus immune activation (9, 10). These APCs promote inflammation and development of effectors through direct cell–cell interactions involving B7 (CD80/CD86) and CD40 signals, as well as noncontact-mediated secretion of cytokines. DCs produce several cytokines that promote Th1 differentiation and IFN-γ responses by CD4+ T cells. DC-derived IL-12, IL-18, IL-27, TNF-α, and T1 IFNs are all capable of driving Th1 responses, as is IFN-γ itself. Conventional DCs (cDCs) primarily produce IL-12, whereas T1 IFNs (α/β) are secreted at very high levels by plasmacytoid DCs (pDCs) (11–13).

Because of their critical role in initiating cell fate decisions that balance tolerance and immune activation, it is perhaps not surprising that recent studies highlighted the importance of DCs during abnormal immune responses and autoimmune manifestations. Alterations in Ag presentation, cytokine secretion, maturation, activation state, and migration patterns of DCs were shown to play roles in the development of a variety of autoimmune diseases (14–16).

In this study, we set out to define the role of DCs in the development of a spontaneous autoantibody-mediated autoimmune disease that is not dependent on immunization. Our results demonstrate that, in the IL-2–KO mouse, cDCs and pDCs induce IFN-γ production by CD4+ T cells and drive the autoimmune pathology. These abnormal DC functions play a role in initiating the autoimmune response and are not a consequence of aberrant T cell activation. Clarifying the role of DCs in the pathogenesis of autoimmunity will improve our understanding of disease and may allow us to stop disease progression by specifically targeting these aberrant DC populations.

Materials and Methods

Mice

All mice were used on the BALB/c background. IL-2–KO mice were backcrossed in our laboratory (backcrossed for >10 generations onto the BALB/c background; The Jackson Laboratory). Transgenic mice...
expressing the DO11.10 TCR specific for the chicken OVA323–339 peptide were obtained from Dr. K. Murphy (Washington University, St. Louis, MO). CD28-KO mice were obtained from Dr. J. Bluethurst (University of California San Francisco). IL-12p40−KO and CD11c-DTR transgenic mice were obtained from The Jackson Laboratory. B7.1/B7.2-deficient (B7-KO) mice were obtained from Dr. A. Sharpe (Harvard Medical School, Boston, MA), B cell-deficient (Jh) mice were obtained from Dr. D. Huszar (GenPharm International, Mountain View, CA), and IFN-αR (IFNAR1)- KO mice were obtained from Dr. A. Mellor (Georgia Health Sciences University, Augusta, GA). All mice were bred and maintained in a specific pathogen-free animal barrier facility in accordance with the guidelines of the Laboratory Animal Resource Center of the University of California San Francisco.

**Ab treatment**
pDC depletion was performed by i.p. injection of 20 μg plasmacytoid dendritic cell Ag-1 (PDCA-1) Ab/μg weight three times per week, beginning on day 8 [clone mAb227 (17), provided by Dr. M. Colonna, Washington University School of Medicine, St. Louis, MO]. cDC depletion was performed by i.p. injection of diptheria toxin (DT) into CD11c-DTR transgenic mice at 9, 11, and 13 d of age (3 ng/g weight on day 9; 4 ng/g weight on days 11 and 13). Anti-IFNAR1 mAb [clone MAR1-5A3 (18), generously provided by Dr. R. Schreiber, Washington University School of Medicine] was administered by i.p. injection at 20 μg/g weight three times per week beginning on day 8.

**Staining and flow cytometry**
Splenocytes and lymphocytes were stained with FITC-, PE-, PerCP-, or allophycocyanin-conjugated Abs or tandem fluorochrome Abs following Fc-block (anti-CD16/CD32). For intracellular cytokine staining, cells were stimulated for 4–6 h (at 37°C), treated with brefeldin A (10 μg/ml) for the final 2 h, and then fixed and permeabilized, as previously described (19). T cells were purchased from BD Biosciences or eBioscience. Flow cytometry was performed on a FACSCalibur or LSORTessa (BD, San Jose, CA), and data were analyzed using FCS Express with Diva (DeNovo Software, Los Angeles, CA).

**Cell preparations, purifications, stimulations, and adoptive transfers**
After injection with 4000 U/ml collagenase D, spleens were teased apart, incubated for 30 min at 37°C, pressed through a nylon mesh filter, and subjected to hypotonic RBC lysis. DCs were enriched using the EasySep CD1c-PE positive selection kit (Stem Cell Technologies, Vancouver, BC, Canada), according to the product insert. CD11c<sup>hi</sup> (cDC) or CD11c<sup>lo</sup>/CD11c<sup>−</sup>PE positive selection kit (Stem Cell Technologies, Vancouver, BC, Canada), according to the product insert. CD11c<sup>hi</sup> (cDC) or CD11c<sup>lo</sup>/CD11c<sup>−</sup>PE positive selection kit (Stem Cell Technologies, Vancouver, BC, Canada), according to the product insert.

**Purification of Tregs**
CD4+CD25+Foxp3+ Tregs were purified to 99% purity from spleen and lymph node cell preparations, purifications, stimulations, and adoptive transfers. To address this, we used B7-KO mice to evaluate the importance of APC costimulation to the activation of CD4+ T cells in the IL-2–KO mouse. To address this, we used B7-KO mice to evaluate the importance of APC costimulation to the activation of CD4+ T cells in the IL-2–KO mouse. To address this, we used B7-KO mice to evaluate the importance of APC costimulation to the activation of CD4+ T cells in the IL-2–KO mouse. To address this, we used B7-KO mice to evaluate the importance of APC costimulation to the activation of CD4+ T cells in the IL-2–KO mouse.

**Ex vivo expansion of Tregs**
CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs were purified to 99% purity from spleen and peripheral LN cells of Foxp3<sup>+</sup>GFP<sup>+</sup> mice by flow cytometric cell sorting. Purified Tregs were cultured for 8–12 d in the presence of anti-CD3 and anti-CD28–coated 4-5 μm paramagnetic microbeads (Xcycy Therapies, Carlsbad, CA) and recombinant human IL-2 (2000 U/ml, Chiron, Emeryville, CA) for 6 d, as previously described (22). Expanded Tregs were depleted of Xcycy beads using a EasySep magnet and washed three times in PBS immediately prior to in vivo injection.

**Statistical analysis**
Statistical differences between experimental groups were determined by the paired t test using Prism software (GraphPad, La Jolla, CA). Bar graphs indicate means; error bars represent SD.

**Results**
APCs, but not B cells, are required for T cell activation during autoimmune immunity

We previously demonstrated that IFN-γ is required for the early autoimmune disease that develops in IL-2–deficient mice (6). Therefore, it is important to determine what is driving IFN-γ production in the absence of IL-2. Because APCs are a critical component in the generation of Th1 cells, we first asked whether APCs are integral in promoting IFN-γ production by CD4<sup>+</sup> T cells in the IL-2–KO mouse. To address this, we used B7-KO mice to evaluate the importance of APC costimulation to the activation of CD4<sup>+</sup> T cells and IFN-γ production during disease. T cell activation in B7-KO mice is defective because of the inability of APCs to costimulate the T cells through CD28 (23, 24), and lymphocyte numbers are normal in these animals (25). IL-2– B7-KO mice also have normal B and T cell numbers and do not develop early lethal AIHA (data not shown).
Comparing IL-2–KO with IL-2 × B7-KO mice, we found that IL-2 × B7-KO CD4+ T cells remained in a naïve state (CD62Lhi CD44lo), whereas IL-2–KO CD4+ T cells expressed decreased CD62L and elevated CD44, indicating activation (Fig. 1A). To assess the ability of APCs from these mice to induce Th1 differentiation, CD4+ T cells were restimulated ex vivo and stained for IFN-γ. IL-2–KO CD4+ T cells exhibited increased IFN-γ production relative to WT CD4+ T cells, whereas the IL-2 × B7-KO CD4+ T cells did not produce elevated IFN-γ. Thus, in the absence of costimulation by APCs, IL-2–KO CD4+ T cells are not activated and do not produce IFN-γ, indicating that APC–T cell interactions through B7 are necessary for Th1 differentiation and IFN-γ production in the absence of IL-2.

Because either DCs or B cells could be the APC population promoting IFN-γ production through B7, we next asked whether B cells are required for the generation of IFN-γ–producing CD4+ T cells using the IL-2 × JH-KO mouse, which does not develop mature peripheral B cells (26). IL–2–KO CD4+ T cells from these B cell-deficient mice still become activated, as assessed by up-regulation of CD44 and down-regulation of CD62L. Both IL–2–KO and IL–2 × JH-KO CD4+ T cells exhibited similar elevated production of IFN-γ following ex vivo restimulation, suggesting that B cells are not required for IFN-γ production (Fig. 1B). Although the IL–2 × JH-KO CD4+ T cells are activated, expanded, and produce elevated IFN-γ, these mice do not succumb to the early, lethal Ab-mediated autoimmunity (i.e., AIHA) because of the absence of B cells and, thus, the absence of autoantibodies (data not shown). As further evidence that B cells are not required for Th1 differentiation and cytokine production during this autoimmune disease, adoptive transfer of IL–2–KO B cells into IL–2 × B7-KO recipients did not drive IFN-γ production by endogenous T cells (data not shown). These data indicate that APC interactions are necessary for T cell activation and Th1 differentiation during autoimmune disease development but B cells are not necessary for these effects. These data further indicate that other APC populations, presumably DCs, are essential in driving Th1 differentiation and T cell activation in the IL–2–KO setting of autoimmunity.

Because B cells are not the source of the APC-derived B7 signals that are important in priming IL–2–KO CD4+ T cells during autoimmunity, we next evaluated DC numbers and phenotype during disease development to determine whether these cells are dysregulated. At 3 wk of age, splenic pDC (Thy1.2CD11c−PDCA-1+) numbers were increased by 3-fold, and cDC (Thy1.2−CD11c−B220−) numbers were increased by ∼2-fold in the absence of IL–2 compared with WT DCs (Fig. 2A). IL–2–KO pDCs expressed increased levels of surface MHC class II (MHC II), CD40, CD80, and CD86, indicating a more mature, activated phenotype compared with WT. cDCs had decreased MHC II expression.

**FIGURE 1.** Stimulation with APCs, but not B cells, is necessary for IFN-γ production by CD4+ T cells. (A) Elimination of B7 costimulatory proteins. (B) Elimination of peripheral B cells. Surface expression of CD44 and CD62L on LN cells from 3–4-wk-old mice was analyzed by flow cytometry (top panels). LN cells were stimulated with 70 ng/ml PMA and 700 ng/ml ionomycin for 5 h, and cytokine production by CD4+ T cells was measured by intracellular cytokine staining (bottom panels). Bar graphs represent cumulative data from three experiments (n = 3 mice from independent experiments). ***p < 0.001.
expression but increased CD40, CD80, and CD86 expression compared with WT. This suggests that IL-2–KO cDCs may be better at T cell activation compared with WT cDCs, while still efficiently taking up Ag. Thus, in the absence of IL-2, the two major splenic DC populations are expanded and activated.

Because the DCs are phenotypically activated in the absence of IL-2, we next tested the functional capacity of the DCs in vivo. To do this, $5 \times 10^5$ pDCs or $1 \times 10^6$ cDCs were transferred i.v. into IL-2–B7-deficient mice, and cytokine production by endogenous CD4+ T cells was assessed. We previously showed that, in such an experimental system, APC function is provided entirely by the transferred DCs because endogenous APCs lack B7 (24). IL-2–KO cDCs were more efficient at driving IFN-γ production than were their WT counterparts (Fig. 3). IL-2–KO pDCs also promoted IFN-γ production, but less efficiently than cDCs. Neither DC population initiated anti-RBC Ab production or autoimmunity, even after three injections of DCs (data not shown). This is likely because ongoing DC–T cell interactions are required for disease induction. These in vivo data suggest a role for IL-2–KO DCs in initiating production of IFN-γ by CD4+ T cells during early activation, leading to autoimmune disease.

cDCs and pDCs drive early spontaneous autoimmunity

To directly address whether DCs are necessary for Th1 induction and autoimmunity in the IL-2–KO mouse, we specifically depleted cDC and/or pDC populations. cDCs were depleted using the CD11c-DTR mouse (27) crossed to the IL-2–KO mouse. Mice were injected with DT at 9, 11, and 13 d of age, allowing selective reduction of CD11c$^{hi}$ cells (cDCs) for 6 d. Despite such a short-term depletion of cDCs, lethal autoimmunity was delayed in IL-2–KO mice by up to 2 wk. To deplete pDCs, IL–2–KO mice were treated with a mAb to PDCA-1 (17). Elimination of pDCs also delayed the onset of autoimmunity by up to 2 wk (Fig. 4A). Depletion of either DC population in the IL–2–KO mice resulted in a significant increase in hemoglobin levels (Fig. 4B) and a reduction in the percentage of RBCs bound by Ab relative to untreated mice.

**FIGURE 2.** DCs are activated and expanded in the absence of IL-2. Collagenase-treated splenocytes from 18–24-d-old WT or IL–2–KO mice were stained and analyzed by flow cytometry. (A) Absolute splenic DC numbers of six individual mice from at least four experiments. (B) FACS profiles of pDCs gated on Thy1.2$^+$ CD11c$^+$B220$^+$PDCA-1$^+$ cells (top panels). Mean fluorescence intensity (MFI) from at least five individual mice (bottom panels). (C) FACS profiles of cDCs gated on Thy1.2$^+$ CD11c$^+$B220$^-$ cells (top panels). MFI from at least five individual mice (bottom panels). Numbers in (B) and (C) represent the MFI of WT cells (gray upper number) and IL–2–KO cells (bold lower number). Representative FACS data are from six individual mice and at least four experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
Depletion of both DC populations had no additive effect on survival, anti-RBC Ab production, or hemoglobin levels (data not shown). Finally, depletion of either cDCs or pDCs resulted in a significant reduction in CD4+ T cell activation (CD69 expression) and IFN-γ production on day 15 (Fig. 4D, 4E). Together, these data indicate that DCs are important for the initiation of early lethal autoimmunity in the absence of IL-2.

**IL-12 and T1 IFN signaling contributes to autoimmune disease**

Because early autoimmunity in the IL-2–KO mouse is Th1 mediated, and the Th1 response requires DC activation, we measured production of Th1-inducing cytokines by DCs. Sorted DCs were stimulated for 24 h, and cytokine mRNA was analyzed by real-time PCR (Fig. 5A). Cytokine mRNA for several Th1-inducing cytokines, including IL-12 and T1 IFN, was elevated in IL-2–KO DCs compared with WT. IL-12 signaling is a strong inducer of IFN-γ production, thus we sought to verify that production of IL-12 protein was also elevated. Both pDCs and cDCs from IL-2–KO mice produced higher levels of p40 (the cytokine subunit found in both IL-12 and IL-23) in response to LPS than did WT cDCs (Fig. 5B). T1 IFNs are the principal cytokines produced by pDCs and function, in part, to drive Th1-effector differentiation. IL-2–KO pDCs stimulated with CpG for 24 h secreted three times more IFN-α than did WT pDCs (Fig. 5C). Thus, in the absence of IL-2 and upon stimulation, DCs produce elevated levels of cytokines known to induce Th1 differentiation of CD4+ T cells.

To determine whether these Th1-inducing cytokine signals from activated DC populations are important for early autoimmunity and elevated IFN-γ production in the absence of IL-2, we eliminated IL-12 and T1 IFN signals. First, IL-2–KO mice were crossed with mice lacking IL-12p35 (IL-23p35-KO) or IL-12p40 (IL-23p40-KO; p40 is also a subunit of IL-23). Kaplan–Meier survival curves of IL-2–KO, IL-2–KO × p35-KO, and IL-2–KO × p40-KO mice
showed that elimination of IL-12 from IL-2–KO mice had a significant impact on autoimmune development and survival (Fig. 6A, data not shown). The mean percentage of RBCs coated with Abs was decreased in the absence of IL-12/23 (36.8% for IL-2–KO RBCs and 23.0% for IL-2 p40-KO RBCs), although this change was not significant (Fig. 6B). In contrast, hemoglobin levels in IL-2–KO mice increased significantly with the elimination of IL-12 signaling, indicating a decrease in anemia (Fig. 6C). This difference between RBC-directed Abs and hemoglobin levels may indicate that, although self-antibodies had begun to form, RBC destruction by the immune system had not yet resulted in the loss of hemoglobin. Thus, IL-12 plays a role in the induction of autoimmunity in the absence of IL-2, because its elimination augments survival of a portion of IL-2–KO mice and delays RBC destruction.

We next asked whether T1 IFN signaling is important for the development of early autoimmunity in the absence of IL-2. To address this question, IL-2–KO mice were crossed with IFNAR1-KO mice, and IL-2 p40-KO mice were treated with an anti-IFNAR1 Ab. Elimination of T1 IFN signals significantly delayed anemia and prolonged survival of IL-2–KO mice, even more than did elimination of IL-12. Blockade of both IL-12 and T1 IFN signals had a small additional effect on the onset of autoimmunity compared with elimination of IL-12 alone (Fig. 6A). Elimination of IL-12 and IFN signals reduced the percentage of RBCs bound by Ab (Fig. 6B) and increased the hemoglobin levels (Fig. 6C) compared with IL-2–KO mice. These data suggest that Th1-mediated induction of autoantibodies resulting in anemia and lethal autoimmunity is promoted, in part, by IL-12 and T1 IFN signals. Further, T1 IFN signals have a stronger influence on disease than do IL-12 signals. The incomplete protection provided by removing these signals suggests that other mechanisms may contribute to the genesis and/or progression of autoimmunity.

Abnormal DC function is partially independent of T cell activation

It is possible that activation of DCs is a consequence of uncontrolled T cell responses in IL-2–KO mice. To determine whether T cell activation is required for the altered DC phenotype, we used IL-2 × CD28-KO mice, which demonstrate no overt T cell expansion or activation at 3–4 wk of age and do not develop AIHA (5). pDC numbers in IL-2 × CD28-KO mice were expanded by 3-fold relative to WT pDCs, similar to abnormally high IL-2–KO pDC numbers (Fig. 7A). cDC numbers from a couple of IL-2 ×
CD28-KO mice were slightly elevated but, combined, the data were not significant. Phenotypic analyses showed that CD40 and MHC II expression on IL-2 × CD28-KO DCs was altered compared with WT mice, but generally less so in IL-2–KO mice (Fig. 7B, 7C). Thus, in the absence of T cell activation (CD28-KO), IL-2–KO pDCs and cDCs demonstrate an intermediate activation state between that of WT and IL-2–KO DCs. These data indicate that the initial activation and maturation of DCs in IL-2–KO mice is partially independent of T cell activation and effector function.

To evaluate DC functionality in the absence of overt T cell activation, DCs from IL-2–KO and IL-2 × CD28-KO mice were compared for their ability to stimulate proliferation of naive T cells. DO11.10 CD4+ T cells were cocultured with sorted DCs (at a 5:1, 10:1, or 20:1 ratio) in the presence of OVA peptide for 3 d (cDC) or 5 d (pDC), and proliferation was measured by CFSE dilution. DO11.10 CD4+ T cells displayed similar levels of proliferation in the presence of each cDC population (Fig. 7D). We also assessed proliferation of WT and IL–2–KO cDCs at various doses of OVA peptide with similar proliferation results (Supplemental Fig. 1). In contrast, DO11.10 CD4+ T cells proliferated to a greater extent when stimulated by IL–2–KO or IL–2 × CD28-KO pDCs than when stimulated by WT or CD28-KO pDCs. These data indicate that the functional state of pDCs is independent of aberrant T cell activity, whereas that of cDCs appears to be dependent on T cell activation. These data further suggest that increased pDC maturation and function in IL–2–KO mice occurs prior to and largely independently of T cell alterations.

**Tregs can control pDC activation**

Recent studies indicated that Tregs can inhibit DC expansion and activation (28–30). Because decreased Tregs are the major defect in the IL–2–KO mouse, it is possible that the absence of Tregs allows the activation of DCs. To test whether WT Tregs are capable of controlling IL–2–KO DCs, we adoptively transferred in vitro-expanded Tregs into these mice and analyzed DC activation markers. Tregs were sorted from Foxp3GFP+ mice and expanded in vitro. A total of 2–4 × 10^6 expanded Tregs was administered by i.p. injection at days 8 and 12 into recipient mice, and DC activation markers were evaluated on day 16. Adoptive transfer of Tregs reduced the expression of MHC II and CD40 on the surface of IL–2–KO pDCs to levels at or near those of WT pDCs (Fig. 8). IL–2–KO cDCs expressed slightly higher MHC II and lower CD40 following the addition of Tregs, trending toward WT levels, but not reaching significance. These data indicate that pDCs may be a primary target of Tregs, whereas in our model, cDC activation is not fully controlled by Tregs. Our data further suggest that pDC activation can act as an initiating event in the development of autoimmunity.
Discussion

In this study, we showed that DC expansion and activation is a critical step in the development of a systemic autoimmune disease. When DC numbers are reduced, Ab development and lethal disease are significantly delayed in the IL-2−/− KO mouse. Our data suggest that, in the absence of control by Tregs, dysregulated DCs initiate early autoimmune events; once autoimmunity is initiated, it is further propagated by these DCs, establishing an amplification loop between DCs and T cells that exacerbates disease.

It is striking that depletion of cDCs for a short duration significantly prolonged survival of IL-2−/− KO mice. At 10 d of age, the first signs of T cell activation can already be observed in IL-2−/− KO mice; thus, elimination of cDCs at this stage removes their influence on the propagation of autoimmunity. Our evaluation of mice; thus, elimination of cDCs at this stage removes their influence on the propagation of autoimmunity. Our evaluation of cDC phenotype and functionality in the absence of T cell activation (IL-2 × CD28−/− KO mice) indicates that cDC alterations are less severe in these mice, suggesting that activation of cDCs is partially dependent on T cells.

In contrast, the activation and function of IL-2−/− KO pDCs appears to be largely independent of T cell activation. IL-2−/− KO pDCs are functionally activated, even in the absence of endogenous T cell activation, and these pDCs induce elevated proliferation of naive T cells relative to WT pDCs. Depletion of pDCs or inhibition of T1 IFN signaling impaired the development of autoantibodies and lethal autoimmunity. One outcome of pDC depletion was the decrease in IFN-γ production, which is known to promote early autoimmunity in these mice (6). IL-2−/− KO pDCs produced elevated IFN-α and contributed to the elevated expression of IL-12, cytokines that stimulate Th1 differentiation and IFN-γ production. Because disease in the IL-2−/− KO mouse is Th1 mediated, it is tempting to hypothesize that pDCs preferentially drive Th1 responses. There are some data to support this idea. For example, flt3L-induced pDCs augment Th1 cytokine production following respiratory syncytial virus infection (31). Together, our data indicate that pDCs and cDCs may have a central role in regulating autoreactive Th1 responses and autoantibody production, thereby inducing Ab-mediated autoimmunity.

Peripheral tolerance and maintenance of immune homeostasis require a careful balance of effector T cells and Tregs. Because of their pivotal role in regulating immune responses, Tregs might be expected to impact the functional maturation state of DCs. Indeed, several recent studies identified a role for Tregs in controlling tolerance through the maintenance of cDC and pDC activation (28, 29, 32). It was proposed that, during homeostasis, an increase in DC numbers results in a subsequent increase in Tregs through MHC II interactions (33). In the absence of IL-2, when Treg percentages are low, pDCs upregulate MHC II, perhaps as a part of the feedback loop that would expand Treg numbers. Because IL-2 is necessary for the survival of peripheral Tregs, the high MHC II expression on IL-2−/− KO pDCs would not alter Treg numbers. Instead, high MHC II expression on IL-2−/− KO pDCs may drive the expansion and activation of effector T cells. We found that addition of WT Tregs reduced MHC II and CD40 expression on IL-2−/− KO pDCs to levels near those of WT pDCs, but it altered these markers only slightly on cDCs. In some models, Tregs were shown to prevent induction of CD80 and CD86 by Ag-specific T effector cells (29, 30), and MHC II or CD40 on mature DCs (28). Our data, in combination with published studies, suggest that DCs can be a primary target of Tregs and that DC activation can act as an initiating event in the development of autoimmunity.

In this systemic autoimmune model, elimination of IL-2 (and, thus, reduced Treg numbers and functionality) is the likely cause of DC dysregulation. Our data support the idea that Treg-mediated suppression of DCs normally acts as one mechanism to control an autoreactive response. In the absence of IL-2, when Tregs are reduced or their function is impaired, DCs upregulate activation and maturation markers, become functionally altered, and can initiate autoimmunity.

An alternative mechanism for altered DC function involves a direct effect of IL-2 on DC development. Recent work by Lau-Kilby et al. (34) demonstrated that IL-2 inhibits the flt3L-dependent generation of pDCs and cDCs. Because the feedback loop between DCs and Tregs proposed by Darrasse-Jéze et al. (33) also required flt3L, these two mechanisms for DC activation may not be mutually exclusive. Lau-Kilby et al. (34) observed a reduced capacity of both pDCs and cDCs to stimulate T cell proliferation when grown in the presence of IL-2. We found that IL-2−/− KO pDCs, but not cDCs, promoted increased T cell proliferation (Fig. 7D, Supplemental Fig. 1). The difference in DC capacity to drive T cell division between these studies may reflect the source of the cDCs (in vivo-derived splenic DCs versus in vitro bone marrow-derived DCs), other factors in vivo that alter the functionality of IL-2−/− KO cDC, or the genetic background and TCR transgene used. These and other recent studies clearly demonstrated the importance of DCs to the dysregulated environment of autoimmune disease and are beginning to clarify the role of IL-2 and Tregs in DC maturation and function.

Our data support the existence of an amplification loop between DCs and CD4+ T cells that is normally controlled, in part, by Tregs. When IL-2 is absent or limiting, Treg numbers are reduced and pDCs become dysregulated, upregulating MHC II and CD40. Mature, activated DCs interact with naive T cells through CD80/CD86 and secretion of IFN-α or IL-12 to promote the expansion of Th1 effector cells. The activated effector cells produce IFN-γ that acts on both pDCs and cDCs to further promote their activation, driving the upregulation of CD80/CD86 and expanding DC numbers. These DCs propagate the differentiation and expansion of Th1 effector cells, likely through IL-12 and IFN-α secretion, ultimately resulting in autoimmune disease. We conclude that autoimmune disease in this model is initiated by pDCs, whose activation and expansion are not properly controlled by Tregs.

Acknowledgments

We thank Dr. Abul Abbas for support and mentorship, Dr. Robert Schreiber (Washington University School of Medicine) for generously providing the anti-IFNAR1 Ab, Drs. Qizhi Tang and Michelle Hermiston for helpful discussions, Dr. Shu-wei Jiang for cell sorting, Carlos Benitez for mouse typing, and the University of California San Francisco Mouse Pathology Core for assistance with complete blood counts.

Disclosures

The authors have no financial conflicts of interest.

References


Supplemental Figure 1: Various doses of OVA peptide. To evaluate cDC functionality in the absence of overt T cell activation, flow-sorted cDCs were cultured with DO11.10 CD4+ T cells and increasing dose of OVA peptide (323-339) for 3 days. Proliferation was measured by CFSE dilution. Naive DO11.10 CD4+ T cells proliferated to a similar extent when stimulated by WT or IL-2-KO cDCs at all doses.